| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| birinapant | cellular inhibitor of apoptosis 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
15.16 | phase 2 | antagonist |
| birinapant | cellular inhibitor of apoptosis 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
15.16 | phase 2 | inhibitor |
| birinapant | cellular inhibitor of apoptosis 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
15.16 | phase 2 | unknown |
| birinapant | x-linked inhibitor of apoptosis protein | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
3.03 | phase 2 | unknown |
| birinapant | x-linked inhibitor of apoptosis protein | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] Lymphoma[MeSHID:D008223] |
3.03 | phase 2 | antagonist |
| click here to return to the previous page | ||||||||